We feel Skyepharma’s share price performance yesterday was unjustified given the recent strong news flow and future prospects. Skyepharma continues to make excellent progress in multiple areas of the business. The recent recognition of a €10m flutiform® sales milestone highlights the continued strong sales growth of the product whilst work continues in parallel to add additional indications and geographies. The development products SKP-2075 (asthma COPD crossover syndrome) and SKP-2076 (asthma triple therapy) could also potentially add significant value to the group’s respiratory franchise. In our note on the respiratory sector, ‘A very attractive subsector in a year of change’ published 28 January, we highlight the unmet need in respiratory disease and believe the subsector offers rich investment opportunities. We continue to believe that Skyepharma has further strong growth potential.
